The role of obesity in the development of polycystic ovary syndrome

Current Pharmaceutical Design

Volumn 18, Issue 17, 2012, Pages 2482-2491

  Motta, Alicia Beatriz ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Adipokines; Anti mullerian hormone; Cardiovascular risk; Implantation; Infertility; Insulin resistance; Leptin; Obesity; Placenta; Polycystic ovary syndrome

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE TRANSPORTER 4; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LUTEINIZING HORMONE; METFORMIN; MUELLERIAN INHIBITING FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACENTA PROTEIN 14; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; SEX HORMONE BINDING GLOBULIN; SIBUTRAMINE; SOMATOMEDIN C; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; VASPIN;

ABNORMAL FECES COMPOSITION; ADIPOCYTE; ADIPOSE TISSUE; CARBOHYDRATE DIET; CARDIOVASCULAR RISK; CONCEPTION; DEFECATION URGENCY; DYSLIPIDEMIA; EXERCISE; FECES INCONTINENCE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GASTROINTESTINAL REFLUX; GENETIC REGULATION; HUMAN; HYPERANDROGENISM; HYPERTENSION; IMPLANTATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LOW FAT DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; PLACENTA FUNCTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SLEEP APNEA SYNDROME; SPOTTING; WEIGHT REDUCTION;

EID: 84860478440     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128112092482     Document Type: Review

References (175)

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 11: 456-88.
2. Abbott D, Dumesic D, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002; 174: 1-5.
3. Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, ed. Polycystic ovary syndrome. Boston: Blackwell Scientific, 1992; 377-84.
4. Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif AGJ, Haseltine F (eds). In Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992, pp. 377-84.
5. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2003; 81: 19-25.
6. Hartz A, Barboriak P, Wong A, Katayama K, Rimm A. The association of obesity with infertility and related menstrual abonormalities in women. Int J Obes 1979; 3: 57-73.
7. Balen A, Homburg R, Franks S. Defining polycystic ovary syndrome. BMJ 1995; 13: 2968-72.
8. van der Steeg J, Steures P, Eijkemans M, Habbema J, Hompes P, Burggraaff J et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum Reprod 2008; 2: 324-8.
9. Maheshwari A, Stofberg L, Bhattacharya S. Effect of overweight and obesity on assisted reproductive technology a systematic review. Hum Reprod Update 2007; 13: 433-44.
10. Weiss J, Malone F, Emig D, Ball R, Nyberg D, Comstock C et al. Obesity, obstetric complications and cesarean delivery rate-a population- based screening study. Am J Obstet Gynecol 2004; 190: 1091-7.
11. Sebire NJ, Jolly M, Harris JP, Wadsworth J, Joffe M, Beard RW et al. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord 2001; 25: 1175-82.
12. Werler M, Louik C, Shapiro S, Mitchell A. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996; 275: 1089-92.
13. Nohr EA, Bech BH, Davies MJ, Frydenberg M, Henriksen TB, Olsen J. Prepregnancy obesity and fetal death: a study within the Danish National Birth Cohort. Obstet Gynecol 2005; 106: 250-9.
14. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan BMC Med 2001; 30: 41-51.
15. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
16. Franks S, Robinson S, Willis D. Nutrition, insulin and polycystic ovary syndrome. Rev Reprod 1996; 1: 47-53.
17. NIH. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. Evidence report. National Institutes of Health. Obes Res 1998; 6: 51S-209S.
18. Clark A, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705-12.
19. Hollmann M, Runnebaum B, Gerhard I. Effects ofweight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996; 11: 1884-91.
20. Huber-Buchholz M, Carey D, Norman R. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-4.
21. Alvarez-Blasco F, Botella-Carretero J, San Millán J, Escobar-Morreale H. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166: 2081-6.
22. Sam S, Legro R, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic sydrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4797-802.
23. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74.
24. Kiddy D, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed M et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105-11.
25. Legro R, Strauss J. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002; 78: 569-76.
26. Stewart DR, Dombroski BA, Urbanek M, Ankener W, Ewens KG, Wood JR et al. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J Clin Endocrinol Metab 2006; 91: 4112-7.
27. Talbot J, Bicknell E, Rajkhowa M, Krook A, O'Rahilly S, Clayton R. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1996; 81: 979-1983.
28. Tan S, Scherag A, Janssen O, Hahn S, Lahner H, Dietz T et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet 2010; 11: 2-9.
29. Catenacci V, Hill J, Wyatt H. The obesity epidemic. Clin Chest Med 2009; 30: 415-44.
30. Ridker P, Hennekens C, Buring J, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl Med 2000; 342: 836-43.
31. Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
32. Koenig W, Sund M, Frohlich M, Fischer H-G, Lowel, H, Doring A et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle- aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 2: 237-42.
33. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner S. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
34. Pradhan A, Manson J, Rifai N, Buring J, Ridker, P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Ass 2001; 286: 327-34.
35. Ridker P, Buring J, Cook N, Rafai N. C-reactive protein, the metabolic syndrome and the risk of incident cardiovascular events: an 8- year follow up of 14719 initially healthy American women. Circulation 2003; 107: 391-7.
36. Carmina E, Orio F, Palomba S, Cascella T, Longo R, Colao A et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005; 152: 389-94.
37. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I et al. Indices of low- grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21: 1426-31.
38. Orio F, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 2-5.
39. Puder J, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to lowgrade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 6014-21.
40. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592-6.
41. Bickerton A, Clark N, Meeking D, Shaw K, Crook M, Lumb P et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005; 58: 151-4.
42. Escobar-Morreale H, Villuendas G, Botella-Carretero J, Sancho J, San Millan J. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003; 46: 625-33.
43. Meyer C, McGrath B, Teede H. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005; 90: 5711-6.
44. Topcu S, Caliskan M, Ozcimen E, Tok D, Uckuyu A, Erdogan D et al. Do Young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease? Hum Reprod 2006; 21: 930-5.
45. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen J. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649-54.
46. Talbot J, Bicknell E, Rajkhowa M, Krook A, O'Rahilly S, Clayton R. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1996; 81: 1979-83.
47. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592-6.
48. Puder J, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to lowgrade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 6014-21.
49. Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G et al. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 737-45.
50. Kelly C, Lyall H, Petrie J, Gould G, Connell J, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-5.
51. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
52. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63.
53. Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li F et al. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diab Res Clin Pract 2006; 72: 244-50.
54. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker A et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obst Gynecol 2003: 101: 1177-82.
55. Vgontzas A, Trakada G, Bixler E, Lin H, Pejovic S, Zoumakis E et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006; 55: 1076-82.
56. Chazenbalk G, Trivax BS, Yildiz BO, Bertolotto C, Mathur R, Heneidi S et al. Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. J Clin Endocrinol Metab 2010; 95: 935-42.
57. Ardawi M, Rouzi A. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 1708-16.
58. Carmina E, Orio F, Palomba S, Longo R, Cascella T, Colao A et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006; 119: 1-6.
59. Moran L, Noakes M, Clifton P, Wittert G, Belobrajdic D, Norman R. C-Reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2944-51.
60. Norman R, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996; 66: 942-7.
61. Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 153-9.
62. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary síndrome. Hum Reprod 2001; 16: 1255-60.
63. Kahn H. The "lipid accumulation product" performs better tan the body mass index for recognizing cardiovascular risk: a populationbased comparison. BMC Cardiovascular Dis 2005; 8: 26-30.
64. Brisson D, Perron P, Guay S, Gaudet D, Bouchard L. The hypertriglyceridemic waist phenotype and glucose intolerance in pregnancy. Can Med Assoc J 2010; 182: 722-5.
65. Wiltgen D, Benedetto I, Mastella L, Spritzer P. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary síndrome. Hum Reprod 2009; 24: 1726-31.
66. Webber L, Stubbs S, Stark J, Trew G, Margara R, Hardy K et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003; 362: 1017-21.
67. McIlveen M, Skull J, Ledger W. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 2007; 22: 778-85.
68. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri D, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? Br J Obstet Gynaecol 2005; 112: 1384-90.
69. Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mu llerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 941-5.
70. Fleming R, Harborne L, MacLaughlin D, Ling D, Norman J, Sattar N et al. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005; 83: 130-6.
71. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen J. Serum anti-Mullerian hormone levels remain high until ate reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20: 1820-6.
72. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk F, Paulson R. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 2007; 87: 870-5.
73. Eldar-Geva T, Margalioth E, Gal M, Ben-Chetrit A, Algur N, Zylber-Haran E et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005; 20: 1814-9.
74. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007; 134: 196-201.
75. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173-9.
76. Moran L Noakes M, Clifton P, Tomlinson L, Norman R. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812-9.
77. Van Dam EW, Roelfsema F, Veldhuis JD, Hogendoorn S, Westenberg J, Helmerhorst FM et al. Retention of estradiol negative feedback relationship to LH predicts ovulation in response to caloric restriction and weight loss in obese patients with polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2004; 286: 615-20.
78. Thomson R, Buckley J, Moran L, Noakes M, Clifton P, Norman R et al. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009; 24: 1976-81.
79. Rich-Edwards J, Goldman M, Willett W, Hunter D, Stampfer M, Colditz G et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 1994: 171: 171-7.
80. Grodstein F, Goldman M, Cramer D. Body mass index and ovulatory infertility. Epidemiology 1994; 5: 247-50.
81. Hassan M, Killick S. Negative lifestyle is associated with a significant reduction in fecundity. Ferti Steril 81; 384-92.
82. Zaadstra B, Seidell J, Van Noord P, te Velde E, Habbema J, Vrieswijk B et al. Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. Br Med J 1993: 306: 484-7.
83. Norman R, Clark A. Obesity and reproductive disorders: a review. Reprod Fertil Dev 1998; 10: 55-63.
84. Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. Reprod Biom Online 2006; 12: 542-51.
85. Plymate SR, Matej LA, Jones RE. Inhibition of sex hormonebinding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67: 460-4.
86. Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 1993; 76: 273-4.
87. Gambineri, A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Rel Metab Dis 2002; 26: 883-96.
88. Chen C, Smothers J, Lange A, Nestler JE, Strauss Iii JF, Wickham Iii EP. Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome. Minerva Endocrinol 2010; 35:271-80.
89. Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide- induced lipogenesis regulates the human hepatic sex hormone- binding globulin gene. J Clin Invest 2007; 17: 3979-87.
90. Leenen R, van der Kooy K, Seidell J, Deurenberg P, Koppeschaar H. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab 1994; 78: 1515-20.
91. Butzow T, Lehtovirta M, Siegberg R, Hovatta O, Koistinen R, Seppala M et al. The decrease in luteinizing hormone secretion in response to weight reduction is inversely related to the severity of insulin resistance in overweight women. J Clin Endocrinol Metab 2000; 85: 3271-5.
92. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994; 61: 598-604.
93. Pasquali R, Gambineri A, Cavazza C, Gasparini DI, Ciampaglia W, Cognigni GE et al. Heterogeneity in the responsiveness to longterm lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011; 164: 53-60.
94. Consensus on infertility treatment related to polycystic ovary syndrome. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Hum Reprod 2008; 23: 462-77.
95. Poretsky L, Cataldo N, Rosenwaks Z, Giudice L. The insulin related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-82.
96. Fulghesu A, Sanna F, Uda S, Magnini R, Portoghese E, Batetta B. IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance. Med Inflam 2011; Epub 2011 Mar 20, ISSN 0749-6524.
97. Licinio J, Mantzoros C, Negrao A, Cizza G, Wong M, Bongiorno P et al. Human leptin levels are pulsatile and inversely related to pituitary- adrenal function. Nat Med 1997; 3: 575-9.
98. Messinis I, Milingos S. Leptin in human reproduction. Hum Reprod Update 1999; 5: 52-63.
99. Tamer Erel C, Senturk L. The impact of body mass index on assisted reproduction. Curr Op Obstet Ginecol 2009; 21: 228-35.
100. Brannian J, Hansen K. Leptin and ovarian folliculogenesis: implications for ovulation induction and ART outcomes. Sem Reprod Med 2002; 20: 103-12.
101. Mounzih K, Lu R, Chehab F. Leptin treatment rescues the sterility of genetical obese ob/ob mice. Endocrinology 1997; 138: 1190-3.
102. Belgorosky D, Sander V, Di Yorio M, Faletti A, Motta A. Hyperandrogenism alters intraovarian parameters during early folliculogenesis in mice. Reprod Biomed Online 2010; 20: 797-807.
103. Agarwal S, Vogel K, Weitsman S, Magoffin D. Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J Clin Endocrinol Metab 1999; 84: 1072-6.
104. Cervero A, Horcajadas J, Dominguez F, Pellicer A, Simon C. Leptin system in embryo development and implantation: a protein in search of a function. Reprod Biomed Online 2005; 10: 217-23.
105. Duggal P, Van Der Hoek K, Milner C, Ryan N, Armstrong D, Magoffin D et al. The in vivo and in vitro effects of exogenous leptin on ovulation in the rat. Endocrinology 2000; 141: 1971-6.
106. Sir-Petermann T, Piwonka V, Perez F, Maliqueo M, Recabarren S, Wildt L. Are circulating leptin and luteinizing hormone synchronized in patients with polycystic ovary syndrome? Hum Reprod 1999; 14: 1435-9.
107. Morin-Papunen L, Koivunen R, Tomas C, Ruokonen A, Martikainen H. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2566-8.
108. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fatdistribution, and androgen and insulin levels inabdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767-74.
109. Brewer C, Balen A. The adverse effects of obesity on conception and implantation. Reproduction 2010; 140: 347-64.
110. Gosman G, Katcher H, Legro R. Obesity and the role of gut and adipose hormones in female reproduction. Hum Reprod Update 2006; 12: 585-601.
111. Considine R, Sinha M, Heiman M, Kriauciunas A, Stephens T, Nyce M, Ohannesian J, Marco C, McKee L, Bauer T. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
112. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. An Surg 2004; 240: 236-42.
113. The ESHRE Capri Workshop Group. Nutrition and reproduction in women. Hum Reprod Update 2006; 193-207.
114. Pierre P, Froment P, Negre D, Rame C, Barateau V, Chabrolle C et al. Role of adiponectin receptors, AdipoR1 and AdipoR2, in the steroidogenesis of the human granulosa tumor cell line, KGN. Hum Reprod 2009; 24: 2890-901.
115. Toulis K, Goulis D, Farmakiotis D, Georgopoulos N, Katsikis I, Tarlatzis B et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a metaanalysis. Hum Reprod Update 2009; 15: 297-307.
116. Escobar-Morreale H, Villuendas G, Botella-Carretero J, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 2006; 21: 2257-65.
117. Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing hormone secretion and ovulation in the rat. Endocrinology 1990; 127: 849-56.
118. Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009; 25: 241-5.
119. Martínez-García M, Luque-Ramírez M, San-Millán J, Escobar-Morreale H. Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. Diab Care 2009; 32: 1525-30.
120. Walch K, Grimm C, Zeillinger R, Huber J, Nagele F, Hefler L. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril 2004; 81: 1638-41.
121. Glueck C, Wang P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 2003; 52: 1627-32.
122. Bruun J, Verdich C, Toubro S, Astrup A, Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-a. Effect of weight loss in obese men. Eur J Endocrinol 2003; 148: 535-42.
123. Watanobe H, Hayakawa Y. Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin- induced suppression of the reproductive axis in rats. Endocrinology 2003; 144: 4868-75.
124. Clark D, Croitoru K. TH1/TH2, 3 imbalance due to cytokine producing NK, gamma delta T and NK-gammadelta T cells in murine pregnancy decidua in success or failure of pregnancy. Am J Reprod Immunol 2001; 45: 257-65.
125. Gutierrez G, Malan Borel I, Margni R. The placental regulatory factor involved in the asymmetric IgG antibody synthesis responds to IL-6 features. Am J Reprod Immunol 2001; 49: 21-32.
126. Szekeres-Bartho J, Polgar B, Kozma N, Miko E, Par G, Szereday L et al. Progesterone-dependent immunomodulation. Chem Immunol Allergy 2005; 89:118-25.
127. Szekeres-Bartho S, Par G, Szereday L, Smart C, Achacz I. Progesterone and non-specific immunological mechanisms in pregnancy. Am J Reprod Immunol 1997; 38: 176-82.
128. Polgar B, Nagy E, Miko E, Varga P, Szekeres-Bartho J. Urinary PIBF (progesterone-induced blocking factor) concentration is related to pregnancy outcome. Biol Reprod 2004; 71: 1699-705.
129. Lee CL, Lam KK, Koistinen H, Seppala M, Kurpisz M, Fernandez N et al. Glycodelin-A as a paracrine regulator in early pregnancy. J Reprod Immunol 2011; 90: 29-34.
130. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol 1996; 31: 81-95.
131. Szereday L, Varga P, Szekeres-Barthó J. Cytokine production in pregnancy. Am J Reprod Immunol 1997; 38: 418-22.
132. Luchetti CG, Mikóc E, Szekeres-Barthoc J, Paz D, Motta AB. Dehydroepiandrosterone and metformin modulate progesteroneinduced blocking factor (PIBF), cyclooxygenase 2 (COX2) and cytokines in early pregnant mice. J Steroid Biochem Mol Biol 2008; 111: 200-7.
133. Jakubowicz D, Essah PA, Seppala M, Jakubowicz S, Baillargeon JP, Koistiene R et al. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with Polycystic Ovary Syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004; 89: 833-9.
134. Gosman G, Katcher H, Legro R. Obesity and the role of gut and adipose hormones in female reproduction. Hum Reprod Update 2006; 12: 585-601.
135. Korgun ET, Denir R, Hammer A, Dohr G, Desoye G, Skofitch G et al. Glucose transporter expression in rat embryo and uterus during decidualization, implantation, and early postimplantation. Biol Reprod 2001; 65:1364-70.
136. Strowitzki T, Capp E, von Wolff M, Mùller-Hòcker J. Expression of glucose transporter 1 in human endometrial and decidual tissue. Gynecol Endocrinol 2001; 15: 219-24.
137. Mioni R, Chiarelli S, Xamin N, Zuliani L, Granzotto M, Mozzanega B et al. Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J Clin Endocrinol Metab 2004; 89: 4089-96.
138. Strowitzki T, von Eye H, Kellerer M, Haring H. Tyrosine kinase activity of insulin-like growth factor I and insulin receptors in human endometrium during the menstrual cycle: cyclic variation of insulin receptor expression. Fert Steril 1993; 59: 315-22.
139. Carrell D, Jones K, Peterson C, Aoki V, Emery B, Campbell B. Body mass index is inversely related to intrafollicular HCG concentrations, embryo quality and IVF outcome. Reprod Biom Online 2001; 3: 109-11.
140. Fedorcsak P, Dale P, Storeng R, Ertzeid G, Bjercke S, Oldereid N et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod 2004; 19: 2523-8.
141. Dechaud H, Anahory T, Reyftmann L, Loup V, Hamamah S, Hedon B. Obesity does not adversely affect results in patients who are undergoing in vitro fertilization and embryo transfer. European J Obstet Gynecol Reprod Biol 2006; 127: 88-93.
142. Metwally M, Cutting R, Tipton A, Skull J, Ledger WL, Li TC. Effect of increased body mass index on oocyte and embryo quality in IVF patients. Reprod Biomed Online 2007; 15: 532-8.
143. Kim ST, Marquard K, Stephens S, Louden E, Allsworth J, Moley KH. Adiponectin and adiponectin receptors in the mouse preimplantation embryo and uterus. Hum Reprod 2011; 26: 82-95.
144. Carlsen SM, Romundstad P, Jacobsen G. Early second trimester hyperandrogenemia and subsequent preeclampsia: A prospective study. Acta Obstet Gynecol Scand 2004; 84: 117-21.
145. Brosens JJ, Pijnenborg R, Brosens IA. The myometrical junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol 2002; 187: 1416-23.
146. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004; 19: 1734-40.
147. Salvesen KA, Vanky E, Carlsen. Metformin treatment in pregnant women with polycystic ovary syndrome - is reduced complication rate mediated by changes in the uteroplacental circulation? Ultrasound Obstet Gynecol 2007; 29: 433-7.
148. Froment P, Holzenberger M, Monget P. Insuline, métabolisme énergétique et fertilité. Méd Sciences 2001; 17: 817-8.
149. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. End Reviews 1999; 20: 649-88.
150. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-95.
151. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. PNAS 2002; 99: 303-8.
152. Tarrade A, Schoonjans K, Guibourdenche J, Bidart JM, Vidaud M, Auwerx J et al. PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology 2001; 142: 4504-14.
153. Elia E, Pustovrh C, Amalfi S, Devoto L, Motta AB. Link between metformin and the peroxisome proliferator-activated receptor. pathway in the uterine tissue of hyperandrogenized prepubertal mice. Fertil Steril 2011; 95: 2534-7.
154. Jakubowicz DJ, Sépala M, Jakubowicz S, Rodríguez-Armas O, Rivas-Santiago A, Koistinen K. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin like growth factor- binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metabol 2001; 86: 1126-33.
155. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293: 43-53.
156. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan BMC Medicine 2010, 8: 41-8.
157. Cussons A, Watt G, Mori T, Stuckey B. Omega-3 fatty acid supplementation decreases liver fat content in Polycystic Ovary Syndrome: A randomized controlled trial employing proton magnetic resonance spectroscopy. Endocr Metab 2009; 94: 3842-8.
158. Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. J Clin Endocrinol Metab 2000; 85:2463-8.
159. Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, Delkos D et al. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome Endocr Journal 2011; 58: 237-46.
160. Tan B, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD et al. Meformin decreases the adipokines vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and decrease in insulin resistance. Diabetes 2008; 57: 1501-9.
161. Escobar-Morreale HF, Luque-Ramírez M, San-Millán JL. Serum visceral adipose tissue-derived serine protease inhibitor concentrations in human obesity and polycystic ovary syndrome. Diab Care 2009; 32: e6.
162. Sabuncu T, Harma M, Nazligul Y, Kilic, F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fert Steril 2003; 80: 1199-204.
163. Sathyapalan T, Cho LI, Kilpatrick ES, Coady AM, Atkin SL. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin Endocrinol 2008; 69: 931-5.
164. Guerciolini R. Mode of action of orlistat. Int J Ob 1997; 21: S12-S23.
165. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005; 90: 729-33.
166. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Ob 2003; 27: 1437-46.
167. Fleming R, Hopkinson Z, Michael Wallace A, Greer I, Sattar A. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebocontrolled trial. J Clin Endocrinol Metab 2002; 87: 569-74.
168. Moghetti P, Castello R, Negri C. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebocontrolled 6- month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metabolism 2000; 85: 139-146.
169. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled crossover trial. Hum Reprod 2007; 22: 2967-73.
170. Lord JM, Flight I, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. Br Med J 2003; 327: 951-5.
171. Norman R, Dewailly D, Legro R, Hickey T. Polycystic ovary syndrome. Lancet 2007; 370: 685-97.
172. Ohsawa M, Asai M, Masahashi T, Narita O, Tomoda Y, Matsui N. Role of sex-hormone- binding globulin and free sex steroid hormones in hyperandrogenic anovulation. Nihon Sanka Fujinka Gakkai Zasshi 1986; 38: 2081-88.
173. Davies M. Evidence for effects of weight on reproduction in women. Reprod Biom Online 2006; 12: 552-61.
174. Carrington B, Sacks G, Regan L Recurrent miscarriage: pathophysiology and outcome. Curr Op Obstet Gynecol 2005; 17: 591-7.
175. Levens ED, Skarulis MC. Assessing the role of endometrial alteration among obese patients undergoing assisted reproduction. Fertil Steril 2008; 89:1606-8.